234 related articles for article (PubMed ID: 26774701)
21. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
Hosokawa S; Haraguchi G; Sasaki A; Arai H; Muto S; Itai A; Doi S; Mizutani S; Isobe M
Cardiovasc Res; 2013 Jul; 99(1):35-43. PubMed ID: 23631839
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.
Paffett ML; Lucas SN; Campen MJ
Vascul Pharmacol; 2012; 56(1-2):64-73. PubMed ID: 22146233
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial hyperpolarization in pulmonary vascular remodeling. Mitochondrial uncoupling protein deficiency as disease model.
Pak O; Sommer N; Hoeres T; Bakr A; Waisbrod S; Sydykov A; Haag D; Esfandiary A; Kojonazarov B; Veit F; Fuchs B; Weisel FC; Hecker M; Schermuly RT; Grimminger F; Ghofrani HA; Seeger W; Weissmann N
Am J Respir Cell Mol Biol; 2013 Sep; 49(3):358-67. PubMed ID: 23590303
[TBL] [Abstract][Full Text] [Related]
24. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
25. Activation of the phosphatidylinositol 3-kinase/Akt pathway is involved in lipocalin-2-promoted human pulmonary artery smooth muscle cell proliferation.
Wang G; Ma N; Meng L; Wei Y; Gui J
Mol Cell Biochem; 2015 Dec; 410(1-2):207-13. PubMed ID: 26350566
[TBL] [Abstract][Full Text] [Related]
26. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension.
Sutendra G; Dromparis P; Bonnet S; Haromy A; McMurtry MS; Bleackley RC; Michelakis ED
J Mol Med (Berl); 2011 Aug; 89(8):771-83. PubMed ID: 21809123
[TBL] [Abstract][Full Text] [Related]
27. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
Yang J; Li X; Al-Lamki RS; Southwood M; Zhao J; Lever AM; Grimminger F; Schermuly RT; Morrell NW
Circ Res; 2010 Jul; 107(2):252-62. PubMed ID: 20522807
[TBL] [Abstract][Full Text] [Related]
28. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats.
Li G; Liu Y; Zhu Y; Liu A; Xu Y; Li X; Li Z; Su J; Sun L
Lung; 2013 Aug; 191(4):327-36. PubMed ID: 23652350
[TBL] [Abstract][Full Text] [Related]
29. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
Yang J; Li X; Al-Lamki RS; Wu C; Weiss A; Berk J; Schermuly RT; Morrell NW
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):34-42. PubMed ID: 23139294
[TBL] [Abstract][Full Text] [Related]
30. Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension.
Dempsie Y; MacRitchie NA; White K; Morecroft I; Wright AF; Nilsen M; Loughlin L; Mair KM; MacLean MR
Cardiovasc Res; 2013 Jul; 99(1):24-34. PubMed ID: 23519266
[TBL] [Abstract][Full Text] [Related]
31. Platelet-Derived TGF (Transforming Growth Factor)-β1 Enhances the Aerobic Glycolysis of Pulmonary Arterial Smooth Muscle Cells by PKM2 (Pyruvate Kinase Muscle Isoform 2) Upregulation.
Zhu Y; Shu D; Gong X; Lu M; Feng Q; Zeng XB; Zhang H; Gao J; Guo YW; Liu L; Ma R; Zhu L; Hu Q; Ming ZY
Hypertension; 2022 May; 79(5):932-945. PubMed ID: 35232222
[TBL] [Abstract][Full Text] [Related]
32. Visceral adipose tissue-derived serine protease inhibitor prevents the development of monocrotaline-induced pulmonary arterial hypertension in rats.
Sakamoto Y; Kameshima S; Kakuda C; Okamura Y; Kodama T; Okada M; Yamawaki H
Pflugers Arch; 2017 Nov; 469(11):1425-1432. PubMed ID: 28776262
[TBL] [Abstract][Full Text] [Related]
33. Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells.
Rafikov R; Sun X; Rafikova O; Louise Meadows M; Desai AA; Khalpey Z; Yuan JX; Fineman JR; Black SM
Redox Biol; 2015 Dec; 6():278-286. PubMed ID: 26298201
[TBL] [Abstract][Full Text] [Related]
34. NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling.
Barman SA; Chen F; Su Y; Dimitropoulou C; Wang Y; Catravas JD; Han W; Orfi L; Szantai-Kis C; Keri G; Szabadkai I; Barabutis N; Rafikova O; Rafikov R; Black SM; Jonigk D; Giannis A; Asmis R; Stepp DW; Ramesh G; Fulton DJ
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1704-15. PubMed ID: 24947524
[TBL] [Abstract][Full Text] [Related]
35. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
36. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
[TBL] [Abstract][Full Text] [Related]
37. Isoquercitrin protects against pulmonary hypertension via inhibiting PASMCs proliferation.
Zhang Y; Cui Y; Deng W; Wang H; Qin W; Huang C; Li C; Zhang J; Guo Y; Wu D; Guo H
Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):362-370. PubMed ID: 27873355
[TBL] [Abstract][Full Text] [Related]
38. LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension.
Lei S; Peng F; Li ML; Duan WB; Peng CQ; Wu SJ
Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H377-H391. PubMed ID: 32559140
[TBL] [Abstract][Full Text] [Related]
39. miR-223 reverses experimental pulmonary arterial hypertension.
Meloche J; Le Guen M; Potus F; Vinck J; Ranchoux B; Johnson I; Antigny F; Tremblay E; Breuils-Bonnet S; Perros F; Provencher S; Bonnet S
Am J Physiol Cell Physiol; 2015 Sep; 309(6):C363-72. PubMed ID: 26084306
[TBL] [Abstract][Full Text] [Related]
40. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
